Agilent Technologies, Inc. (NYSE:A – Get Rating) SVP Michael Tang sold 3,600 shares of the stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $139.50, for a total value of $502,200.00. Following the sale, the senior vice president now directly owns 43,280 shares in the company, valued at approximately $6,037,560. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Agilent Technologies Trading Down 0.5 %
A stock traded down $0.65 during trading on Thursday, hitting $134.62. 17,194 shares of the company traded hands, compared to its average volume of 1,283,416. The firm has a market capitalization of $39.85 billion, a PE ratio of 30.81, a P/E/G ratio of 2.73 and a beta of 1.06. Agilent Technologies, Inc. has a 1 year low of $112.52 and a 1 year high of $165.68. The company has a 50-day moving average of $130.13 and a 200-day moving average of $126.15. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.41 and a current ratio of 1.94.
Agilent Technologies (NYSE:A – Get Rating) last issued its earnings results on Tuesday, August 16th. The medical research company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.14. The company had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Agilent Technologies had a return on equity of 28.46% and a net margin of 19.94%. Agilent Technologies’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.10 EPS. Analysts predict that Agilent Technologies, Inc. will post 5.07 earnings per share for the current fiscal year.
Agilent Technologies Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 26th. Shareholders of record on Tuesday, October 4th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend was Monday, October 3rd. Agilent Technologies’s dividend payout ratio (DPR) is currently 19.13%.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on Agilent Technologies from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 17th. StockNews.com started coverage on Agilent Technologies in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group started coverage on Agilent Technologies in a research note on Wednesday, August 24th. They issued an “outperform” rating and a $165.00 target price on the stock. Robert W. Baird upped their target price on Agilent Technologies from $155.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 17th. Finally, Citigroup upped their target price on Agilent Technologies from $140.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 17th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $151.31.
Institutional Investors Weigh In On Agilent Technologies
Institutional investors and hedge funds have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA lifted its stake in shares of Agilent Technologies by 42.2% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 5,851,153 shares of the medical research company’s stock valued at $694,942,000 after purchasing an additional 1,736,168 shares during the period. Wellington Management Group LLP lifted its stake in shares of Agilent Technologies by 18.5% in the 1st quarter. Wellington Management Group LLP now owns 10,826,141 shares of the medical research company’s stock valued at $1,432,622,000 after purchasing an additional 1,691,006 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Agilent Technologies by 62.4% in the 2nd quarter. Principal Financial Group Inc. now owns 3,115,931 shares of the medical research company’s stock valued at $370,078,000 after purchasing an additional 1,197,836 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Agilent Technologies by 67.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,336,607 shares of the medical research company’s stock valued at $309,203,000 after purchasing an additional 942,651 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Agilent Technologies by 196.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,242,600 shares of the medical research company’s stock valued at $164,433,000 after purchasing an additional 823,300 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.